There is no accepted standard of care for the chemotherapy treatment of metastatic brain
tumors, which has been generally limited to lipophilic alkylators, which may not have efficacy …

Despite the widely held belief of the resistance to chemotherapy of brain metastases, central
nervous sytem metastases of a malignancy are equally sensitive to chemotherapy as its …

Blocking autophagy with hydroxychloroquine (HCQ) augments cell death associated with
alkylating chemotherapy in preclinical models. This phase I study evaluated the maximum …

Purpose: The DNA repair enzyme O 6-methylguanine DNA methyltransferase (MGMT)
inhibits the killing of tumor cells by alkylating agents, and its loss in cancer cells is …

Temozolomide (Temodal®, Temodar), an imidazol derivative, is a second-generation
alkylating agent. The orally available prodrug with the capacity of crossing the blood–brain …

PURPOSE: Patients with brain metastases (BM) rarely survive longer than 6months and are
commonly excluded from clinical trials. We explored two combined modality regimens with …

Temozolomide (TMZ) was first known to be useful as a radiosensitiser in both primary brain
tumours like glioblastoma multiforme and oligodendroglioma. Later, TMZ proved its efficacy …

INTRODUCTION:: The primary tumour type most likely to metastasize to the brain is lung
cancer. In heavily pre-treated patients, limited therapeutic option is available and the results …

We examined the predictive value of neutrophil–lymphocyte ratio (NLR) by examining their
association with the baseline presence and subsequent development of brain metastases in …

Abstract Background Crizotinib and Temozolomide are the two major chemotherapy drugs
used for the treatment of cancers. Crizotinib is used as a target chemotherapy drug in many …